MiR-1246 Promotes Metastasis and Invasion of A549 Cells by Targeting GSK-3β–Mediated Wnt/β-Catenin Pathway
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose MicroRNAs (miRNAs) are a group of small non-coding RNAs involved in different cancers, including lung cancer. Here, we aim to investigate the expression profiles of circulating miRNAs and their roles contributed to the progress of lung cancer. Materials and Methods The levels of circulating miRNA in lung cancer patients were investigated by miRNAs assay. Then we predicted the target genes of aberrantly expressing miRNAs by searching genetic databases. Based on the A549 cells transfected with miR-1246 mimics or miR-1246 inhibitor, we further measured the roles of miR-1246 involving in the epithelial-mesenchymal transition (EMT), migration and invasion capacities of lung cancer cells in vitro. Finally, we detected the effects of miR-1246 on glycogen synthase kinase-3β (GSK-3β)/β-catenin pathway by immunofluorescence and Western blot, respectively. Results We identified that 14 miRNAs were aberrantly expressed in the serum of lung cancer patients. Among them, miR-1246 was the most up-regulated. The cell assays indicated that miR-1246 significantly increased the migration and invasion capabilities of A549 lung cancer cells. Meanwhile, immunofluorescence analysis revealed that miR-1246 promoted EMT process of A549 cells accompanying with decreasing E-cadherin expression, while increasing vimentin and transforming growth factor β expression. Furthermore, an online tool predicated that miR-1246 might bind to 3'-untranslated region of GSK-3β, which was confirmed by overexpression and knockdown of miR-1246 assays. Conclusion Taken together, the study illustrates that miR-1246 regulates Wnt/β-catenin pathway through targeting GSK-3β/β-catenin, which partly contributing to tumor metastasis. MiR- 1246 may play an essential role in the diagnosis and therapeutic of lung cancer.
Abstract
Purpose MicroRNAs (miRNAs) are a group of small non-coding RNAs involved in different cancers, including lung cancer. Here, we aim to investigate the expression profiles of circulating miRNAs and their roles contributed to the progress of lung cancer. Materials and Methods The levels of circulating miRNA in lung cancer patients were investigated by miRNAs assay. Then we predicted the target genes of aberrantly expressing miRNAs by searching genetic databases. Based on the A549 cells transfected with miR-1246 mimics or miR-1246 inhibitor, we further measured the roles of miR-1246 involving in the epithelial-mesenchymal transition (EMT), migration and invasion capacities of lung cancer cells in vitro. Finally, we detected the effects of miR-1246 on glycogen synthase kinase-3β (GSK-3β)/β-catenin pathway by immunofluorescence and Western blot, respectively. Results We identified that 14 miRNAs were aberrantly expressed in the serum of lung cancer patients. Among them, miR-1246 was the most up-regulated. The cell assays indicated that miR-1246 significantly increased the migration and invasion capabilities of A549 lung cancer cells. Meanwhile, immunofluorescence analysis revealed that miR-1246 promoted EMT process of A549 cells accompanying with decreasing E-cadherin expression, while increasing vimentin and transforming growth factor β expression. Furthermore, an online tool predicated that miR-1246 might bind to 3'-untranslated region of GSK-3β, which was confirmed by overexpression and knockdown of miR-1246 assays. Conclusion Taken together, the study illustrates that miR-1246 regulates Wnt/β-catenin pathway through targeting GSK-3β/β-catenin, which partly contributing to tumor metastasis. MiR- 1246 may play an essential role in the diagnosis and therapeutic of lung cancer.
참고문헌 (27)
- Arif Uddin, "Role of miRNAs in lung cancer", Journal of Cellular Physiology (2018), Wiley[DOI]
- Lin G, "MiR-26a enhances invasive capacity by suppressing GSK3beta in human lung cancer cells", Exp Cell Res, 352, pp.364~374 (2017)
- Jiang W, "MicroRNA-1258 suppresses tumour progression via GRB2", Ras, Cell Prolif, pp.2018, 51[DOI]
- Wu KL, "Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib", Lung Cancer, 88, pp.187~194 (2015)
- Reck M, "Metastatic non-small-cell lung cancer (NSCLC):ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 25(Suppl 3), pp.iii27~iii39 (2014)
- Bica-Pop C, "Overview upon miR-21 in lung cancer : focus on NSCLC", Cell Mol Life Sci, 75, pp.3539~3551 (2018)
- Song L, "miR-144-5p enhances the radiosensitivity of non-small-cell lung cancer cells via targeting ATF2", Biomed Res Int, 2018, pp.5109497~ (2018)
- 김슬기, "Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib", Cancer Research and Treatment, 51(3), pp.951~962 (2019), 대한암학회
- Nowrin K, "Epithelial-mesenchymal transition as a fundamental underlying pathogenic process in COPD airways : fibrosis, remodeling and cancer", Expert Rev Respir Med, 8, pp.547~559 (2014)
- Sung WJ, "The biological role of epithelialmesenchymal transition in lung cancer(Review)", Oncol Rep, 36, pp.1199~1206 (2016)
- Otsuki Y, "Prospects for new lung cancer treatments that target EMT signaling", Dev Dyn, 247, pp.462~472 (2018)
- Martinez-Rivera V, "Secreted and tissue miRNAs as diagnosis biomarkers of malignant pleural mesothelioma", Int J Mol Sci, 19, pp.E195~ (2018)
- Moshiri F, "Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma", Oncotarget, 9, pp.15350~15364 (2018)
- Li L, "Clinical significance of blood-based miRNAs as biomarkers of non-small cell lung cancer", Oncol Lett, 15, pp.8915~8925 (2018)
- Yang Y, "Downregulation of miR-3127-5p promotes epithelial-mesenchymal transition via FZD4 regulation of Wnt", beta-catenin signaling in non-small-cell lung cancer, 2018, pp.57, 842~853
- Baranwal S, "miRNA control of tumor cell invasion and metastasis", Int J Cancer, 126, pp.1283~1290 (2010)
- Skronska-Wasek W, "WNT receptor signalling in lung physiology and pathology", Pharmacol Ther, 187, pp.150~166 (2018)
- Tanaka K, "Intracellular signals of lung cancer cells as possible therapeutic targets", Cancer Sci, 106, pp.489~496 (2015)
- Krishnamurthy N, "Targeting the Wnt", beta-catenin pathway in cancer : update on effectors and inhibitors, 2018, pp.62, 50~60
- Jia Z, "miR-126 suppresses epithelial-to-mesenchymal transition and metastasis by targeting PI3K", AKT, Oncol Lett, pp.2018, 15[DOI]
- Mitchell PS, "Circulating microRNAs as stable blood-based markers for cancer detection", Proc Natl Acad Sci U S A, 105, pp.10513~10518 (2008)
- Kodahl AR, "Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer : a case control study", Mol Oncol, 8, pp.874~883 (2014)
- Ortiz-Quintero B, "Cell-free microRNAs in blood and other body fluids, as cancer biomarkers", Cell Prolif, 49, pp.281~303 (2016)
- Zhang WC, "Tumour-initiating cell-specific miR-1246 and miR-1290expression converge to promote non-small cell lung cancer progression", Nat Commun, 7, pp.11702~ (2016)
- Kim G, "HsamiR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer", Lung Cancer, 91, pp.15~22 (2016)
- Yuan D, "Extracellular miR-1246 promotes lung cancer cell proliferation and enhances radioresistance by directly targeting DR5", Oncotarget, 7, pp.32707~32722 (2016)
- Chai S, "Octamer 4", microRNA-1246 signaling axis drives Wnt, Hepatology, pp.2016, 64[DOI]